Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners
ACOGVANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Alpha Cognition will participate in an upcoming virtual fireside chat hosted by Boris Peaker of Titan Partners. The discussion will focus on commercialization efforts and research initiatives to accelerate commercial adoption. Presentation
Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences
ACOGVANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that Chief Executive Officer Michael McFadden will present at two prominent healthcare investor conferences this September. Cantor Global Healthcare Conference 2025 Date/Time: Friday, September 5, 7:00 a.m. ET H.C. Wainwright & Co. Healthcare Conference 2025 Date/
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
ACOGVANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”) today announced its financial results for the second quarter ended June 30, 2025. “The initial ZUNVEYL launch has been met with strong interest from both healthcare providers and patients. Early adoption in nursing homes and by geriatric specialists has created a solid foundation for future growth,” said Michael McFadden, Chief Executive Officer of Alpha Cogn
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview
ACOGVANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-
HC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $20 Price Target
ACOGAlpha Cognition Q1 EPS $(0.13) Beats $(0.84) Estimate, Sales $2.93M Beat $954.50K Estimate
ACOGEarnings Scheduled For May 15, 2025
ACOGAlpha Cognition To Present ZUNVEYL Clinical Data At 2025 AAIC
ACOGWhy ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
ACOGHC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $20 Price Target
ACOGAlpha Cognition FY 2024 GAAP EPS $(0.51) Misses $(0.08) Estimate
ACOGHC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $20 Price Target
ACOGEarnings Scheduled For March 31, 2025
ACOGAlpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
ACOGHC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
ACOGAlpha Cognition Announces The Official Commercial Launch Of ZUNVEYL, A New Treatment For Mild To Moderate Alzheimer's Disease
ACOGHC Wainwright & Co. Initiates Coverage On Alpha Cognition with Buy Rating, Announces Price Target of $20
ACOGAlpha Cognition Secures Additional U.S. Patent For ZUNVEYL For Treatment Of Mild To Moderate Alzheimer's Disease
ACOGAlpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY
ACOG